

TAVANKIT SINGH, MD

Department of Gastroenterology and Hepatology, Cleveland Clinic

DANIELA S. ALLENDE, MD

Director, Hepatobiliary Pathology, Department of Pathology, Cleveland Clinic; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

ARTHUR J. McCULLOUGH, MD

Departments of Gastroenterology and Hepatology and Pathobiology and Transplantation Center, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Assessing liver fibrosis without biopsy in patients with HCV or NAFLD

ABSTRACT

Staging of liver fibrosis is increasingly done using non-invasive methods, in some cases obviating the need for liver biopsy. Scores based on laboratory values and demographic variables have been developed and validated for assessing fibrosis in patients with hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD), as have several imaging methods that measure shear-wave velocity, a reflection of fibrosis severity.

KEY POINTS

Liver biopsy remains the gold standard for determining fibrosis stage but is expensive and entails risk of complications.

For patients infected with HCV, fibrosis stage should be determined with transient elastography, a transthoracic ultrasonographic technique that measures shear-wave velocity.

For patients with cirrhosis, transient elastography combined with a platelet count can detect developing portal hypertension and determine whether to screen for esophageal varices.

For NAFLD, combined elastography and NAFLD fibrosis score—which incorporates patient characteristics and laboratory test results—should be used to determine the need for liver biopsy.

STAGING OF LIVER FIBROSIS, important for determining prognosis in patients with chronic liver disease and for the need to start screening for complications of cirrhosis, was traditionally done only by liver biopsy. While biopsy is still the gold standard method to stage fibrosis, noninvasive methods have been developed that can also assess disease severity.

This article briefly reviews the epidemiology and physiology of chronic liver disease and the traditional role of liver biopsy. Pros and cons of alternative fibrosis assessment methods are discussed, with a focus on their utility for patients with nonalcoholic fatty liver disease (NAFLD) and hepatitis C virus (HCV) infection.

■ CHRONIC LIVER DISEASE: A HUGE HEALTH BURDEN

Chronic liver disease is associated with enormous health and financial costs in the United States. Its prevalence is about 15%,¹ and it is the 12th leading cause of death.² Hospital costs are estimated at about \$4 billion annually.³

The most common causes of chronic liver disease are NAFLD (which may be present in up to one-third of the US population and is increasing with the epidemic of obesity), its aggressive variant, nonalcoholic steatohepatitis (NASH) (present in about 3% of the population), and HCV infection (1%).^{4,5}

Since direct-acting antiviral agents were introduced, HCV infection dropped from being the leading cause of liver transplant to third place.⁶ But at the same time, the number of patients on the transplant waiting list who have NASH has risen faster than for any other cause of chronic liver disease.⁷

TABLE 1

Fibrosis staging systems for HCV and NAFLD

Stage	Ishak staging for HCV ¹⁰	METAVIR staging for HCV ¹¹	NASH Clinical Research Network staging system for NAFLD ¹²
0	No fibrosis	No fibrosis	No fibrosis
1	Expansion of some portal areas with or without septa	Portal fibrosis without septa	Perisinusoidal or periportal fibrosis
2	Expansion of most portal areas with or without septa	Portal fibrosis with rare septa	Perisinusoidal and portal/periportal fibrosis
3	Expansion of most portal areas with occasional portal-portal bridging	Portal fibrosis with numerous septa	Bridging fibrosis
4	Expansion of portal areas with marked bridging (portal-portal, portal-central)	Cirrhosis	Cirrhosis
5	Marked bridging with occasional nodules (incomplete cirrhosis)		
6	Cirrhosis		

HCV = hepatitis C virus; METAVIR = Meta-analysis of Histological Data in Viral Hepatitis; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis

Fibrosis: a process of collagen deposition in hepatic lobules

FIBROSIS: A KEY INDICATOR OF DISEASE SEVERITY

With any form of liver disease, collagen is deposited in hepatic lobules over time, a process called fibrosis. Both HCV infection and NASH involve necroinflammation in the liver, hepatocyte apoptosis, and activation of stellate cells, leading to progressive collagen deposition in hepatic lobules. Fibrosis typically starts in the region of the central vein and portal tracts and eventually extends to other areas of the lobule.

Determining fibrosis severity is critical when a patient is diagnosed with chronic liver disease, as it predicts long-term clinical outcomes and death in HCV⁸ and NAFLD.⁹ Different staging systems have been developed to reflect the degree of fibrosis, based on its distribution as seen on liver biopsy (Table 1, Figure 1).


In HCV infection, advanced fibrosis is defined as either stage 4 to 6 using the Ishak system¹⁰ or stage 3 to 4 using the Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) system.¹¹

In NAFLD, advanced fibrosis is defined as stage 3 to 4 using the NASH Clinical Research Network system.¹²


Staging fibrosis is also important so that patients with cirrhosis can be identified early to begin screening for hepatocellular carcinoma and esophageal varices to reduce the risks of illness and death. In addition, insurance companies often require documentation of fibrosis stage before treating HCV with the new direct-acting antiviral agents.

LIVER BIOPSY IS STILL THE GOLD STANDARD


Although invasive, liver biopsy remains the gold standard for determining fibrosis stage. Liver biopsies were performed “blindly” (without imaging) until the 1990s, but imaging-guided biopsy using ultrasonography was then developed, which entailed less pain and lower complication and hospitalization rates. Slightly more hepatic tissue is obtained with guided liver biopsy, but the difference was deemed clinically insignificant.¹³ Concern initially




Expansion of portal tract by fibrosis (trichrome stain, × 100)




In the setting of steatohepatitis, fibrosis starts in the centrilobular perisinusoidal region (trichrome stain, × 100)




A subset of nonalcoholic steatohepatitis cases reveals only portal-based fibrosis, consistent with stage 1C (left); the centrilobular region seen on the right is intact (trichrome stain, × 100)



Periportal fibrosis is characterized by expansion of portal tracts with irregular border and focal entrapment of hepatocytes (trichrome stain, × 200)



Bridges of fibrous tissue connecting two portal tracts in a hepatitis C case, supporting stage 3 (bridging fibrosis) (trichrome stain, × 100)



End-stage liver disease with multiple cirrhotic nodules, surrounded by fibrous bands (trichrome stain, × 100)

**Bleeding
is the most
worrisome
complication
of liver biopsy**

Figure 1. Findings on liver biopsy in nonalcoholic fatty liver disease and hepatitis C virus infection.

arose about the added cost involved with imaging, but imaging-guided biopsy was actually found to be more cost-effective.¹⁴

In the 2000s, transjugular liver biopsy via the right internal jugular vein became available. This method was originally used primarily in patients with ascites or significant coagulopathy. At first, there were concerns about the adequacy of specimens obtained to make an accurate diagnosis or establish fibrosis stage, but this limitation was overcome with improved techniques.^{15,16} Transjugular liver biopsy has the additional advantage of enabling one to measure the hepatic venous pressure gradient, which also has prognostic significance; a gradient greater than 10 mm Hg is associated with worse prognosis.¹⁷

Disadvantages of biopsy: Complications, sampling errors

Liver biopsy has disadvantages. Reported rates of complications necessitating hospitalization using the blind method were as high as 6% in the 1970s,¹⁸ dropping to 3.2% in a 1993 study.¹⁹ Bleeding remains the most worrisome complication. With the transjugular method, major and minor complication rates are less than 1% and 7%, respectively.^{15,16} Complication rates with imaging-guided biopsy are also low.

Liver biopsy is also prone to sampling error. The number of portal tracts obtained in the biopsy correlates with the accuracy of fibrosis staging, and smaller samples may lead to underestimating fibrosis stage. In patients with HCV, samples more than 15 mm long led to accurate staging diagnosis in 65% of patients, and those longer than 25 mm conferred 75% accuracy.²⁰ Also, different stages can be diagnosed from samples obtained from separate locations in the liver, although rarely is the difference more than a single stage.²¹

Histologic evaluation of liver biopsies is operator-dependent. Although significant interobserver variation has been reported for degree of inflammation, there tends to be good concordance for fibrosis staging.^{22,23}

STAGING BASED ON DEMOGRAPHIC AND LABORATORY VARIABLES

Several scores based on patient characteristics and laboratory values have been developed for assessing liver fibrosis and have been specifi-

cally validated for HCV infection, NAFLD, or both. They can serve as inexpensive initial screening tests for the presence or absence of advanced fibrosis.

FIB-4 index for HCV, NAFLD

The FIB-4 index predicts the presence of advanced fibrosis using, as its name indicates, a combination of 4 factors in fibrosis: age, platelet count, and the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), according to the formula:

$$FIB-4 \text{ index} = (\text{age} \times \text{AST [U/L]}) / (\text{platelet count} [\times 10^9/L] \times \sqrt{\text{ALT [U/L]}}).$$

The index was derived from data from 832 patients co-infected with HCV and human immunodeficiency virus.²⁴ The Ishak staging system¹⁰ for fibrosis on liver biopsy was used for confirmation, with stage 4 to 6 defined as advanced fibrosis. A cutoff value of more than 3.25 had a positive predictive value of 65% for advanced fibrosis, and to exclude advanced fibrosis, a cutoff value of less than 1.45 had a negative predictive value of 90%.

The FIB-4 index has since been validated in patients with HCV infection²⁵ and NAFLD.²⁶ In a subsequent study in 142 patients with NAFLD, the FIB-4 index was more accurate in diagnosing advanced fibrosis than the other noninvasive prediction models discussed below.²⁷

NAFLD fibrosis score

The NAFLD fibrosis score, constructed and validated only in patients with biopsy-confirmed NAFLD, incorporates age, body mass index, presence of diabetes or prediabetes, albumin level, platelet count, and AST and ALT levels.

A group of 480 patients was used to construct the score, and 253 patients were used to validate it. Using the high cutoff value of 0.676, the presence of advanced fibrosis was diagnosed with a positive predictive value of 90% in the group used to construct the model (82% in the validation group). Using the low cutoff score of -1.455, advanced fibrosis could be excluded with a negative predictive value of 93% in the construction group and 88% in the validation group.²⁸ A score between the cutoff values merits liver biopsy to determine fibrosis stage. The score is more accurate in patients with diabetes.²⁹ When used by prima-

**A NAFLD
fibrosis score
between
the cutoff
values merits
liver biopsy**

ry care physicians, the NAFLD fibrosis score is more cost-effective than transient elastography and liver biopsy for accurately predicting advanced fibrosis.³⁰

AST-to-platelet ratio index score for HCV, NAFLD

The AST-to-platelet ratio index (APRI) score was developed in 2003 using a cohort of 270 patients with HCV and liver biopsy as the standard. A cutoff value of less than or equal to 0.5 had a negative predictive value of 86% for the absence of significant fibrosis, while a score of more than 1.5 detected the presence of significant fibrosis with a positive predictive value of 88%.³¹ The APRI score was subsequently validated for NAFLD.^{27,32}

FibroSure uses a patented formula

FibroSure (LabCorp; labcorp.com) uses a patented mathematical formula that takes into account age, sex, and levels of gamma-glutamyl transferase, total bilirubin, haptoglobin, apolipoprotein-A, and alpha-2 macroglobulin to assess fibrosis. Developed in 2001 for use in patients with HCV infection, it was reported to have a positive predictive value of greater than 90% and a negative predictive value of 100% for clinically significant fibrosis, defined as stage 2 to 4 based on the METAVIR staging system in the prediction model.³³ The use of FibroSure in patients with HCV was subsequently validated in various meta-analyses and systematic reviews.^{34,35} It is less accurate in patients with normal ALT levels.³⁶

FibroSure also has good accuracy for predicting fibrosis stage in chronic liver disease due to other causes, including NAFLD.³⁷

The prediction models discussed above use routine laboratory tests for chronic liver disease and thus are inexpensive. The high cost of additional testing needed for FibroSure, coupled with the risk of misdiagnosis, makes its cost-effectiveness questionable.³⁸

IMAGING TO PREDICT FIBROSIS STAGE

Conventional ultrasonography (with or without vascular imaging) and computed tomography can detect cirrhosis on the basis of certain imaging characteristics,^{39,40} including the nodular contour of the liver, caudate lobe hypertrophy, ascites, reversal of blood flow in the

portal vein, and splenomegaly. However, they cannot detect fibrosis in its early stages.

The 3 methods discussed below provide more accurate fibrosis staging by measuring the velocity of shear waves sent across hepatic tissue. Because shear-wave velocity increases with liver stiffness, the fibrosis stage can be estimated from this information.⁴¹

Transient elastography

Transient elastography uses a special ultrasound transducer. It is highly accurate for predicting advanced fibrosis for almost all causes of chronic liver disease, including HCV infection^{42,43} and NAFLD.⁴⁴ The cutoff values of wave velocity to estimate fibrosis stage differ by liver disease etiology.

Transient elastography should not be used to evaluate fibrosis in patients with acute hepatitis, which transiently increases liver stiffness, resulting in a falsely high fibrosis stage diagnosis.⁴⁵ It is also not a good method for evaluating fibrosis in patients with biliary obstruction or extrahepatic venous congestion. Because liver stiffness can increase after eating,⁴⁶ the test should be done under fasting conditions.

A significant limitation of transient elastography has been its poor accuracy in patients with obesity.⁴⁷ This has been largely overcome with the use of a more powerful (XL) probe but is still a limitation for those with morbid obesity.⁴⁸ Because many patients with NAFLD are obese, this limitation can be significant.

Transient elastography has gained popularity for evaluating fibrosis in patients with chronic liver disease for multiple reasons: it is cost-effective and results are highly reproducible, with low variation in results among different observers and in individual observers.⁴⁹ Combined with a platelet count, it can also be used to detect the development of clinically significant portal hypertension in patients with cirrhosis, thus determining the need to screen for esophageal varices using endoscopy.⁵⁰ Screening endoscopy can be avoided in patients whose liver stiffness remains below 20 kPa or whose platelet count is above $150 \times 10^9/L$.

Acoustic radiation force imaging

Unlike transient elastography, which requires a separate transducer probe to assess shear-wave velocity, acoustic radiation force imaging uses the same transducer for both this

Transient elastography can detect advanced fibrosis for most causes of chronic liver disease




Figure 2. Algorithm to determine fibrosis stage for nonalcoholic fatty liver disease.

function and imaging. Different image modes are available when testing for liver stiffness, so a region of interest that is optimal for avoiding vascular structures or masses can be selected, increasing accuracy.⁵¹

Acoustic radiation force imaging has been tested in different causes of chronic liver disease, including HCV and NAFLD,⁵² with accuracy similar to that of transient elastography.⁵³ For overweight and obese patients, acoustic radiation force imaging is more accurate than transient elastography using the XL probe.⁵⁴ However, this method is still new, and we need more data to support using one method over the other.

Magnetic resonance elastography

Magnetic resonance elastography uses a special transducer placed under the rib cage to transmit shear waves concurrently with magnetic resonance imaging. It has been tested in patients with HCV and NAFLD and has been found to have better diagnostic accuracy than transient elastography and acoustic radiation

force imaging.^{55,56} Patients must be fasting for better diagnostic accuracy⁵⁷ and must hold their breath while elastography is performed. The need for breath-holding and the high cost limit the use of this method for assessing fibrosis.

■ BOTTOM LINE FOR ASSESSING FIBROSIS

Although liver biopsy remains the gold standard for accurately determining fibrosis stage, noninvasive methods, especially imaging techniques, are fast evolving. Guidelines recommend using transient elastography to determine fibrosis stage noninvasively in patients with HCV,⁵⁸ but a similar recommendation cannot be made for NAFLD with available data. For NAFLD, combined elastography and NAFLD fibrosis score are recommended to determine the need for a liver biopsy (Figure 2).⁵⁹ Currently, we recommend using a combination of the scores discussed above and the imaging tests. ■

Transient elastography is cost-effective, and results are highly reproducible

■ REFERENCES


1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol* 2011; 9(6):524-530.e1. doi:10.1016/j.cgh.2011.03.020
2. Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H-C. Deaths: final data for 2009. *Natl Vital Stat Rep* 2011; 60(3):1-116. pmid:24974587
3. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. *Am J Gastroenterol* 2012; 107(2):247-252. doi:10.1038/ajg.2011.314
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; 34(3):274-285. doi:10.1111/j.1365-2036.2011.04724.x
5. Udompap P, Kim D, Kim WR. Current and future burden of chronic nonmalignant liver disease. *Clin Gastroenterol Hepatol* 2015; 13(12):2031-2041. doi:10.1016/j.cgh.2015.08.015
6. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. *Am J Transplant* 2018; 18(suppl 1):172-253. doi:10.1111/ajt.14559
7. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015; 148(3):547-555. doi:10.1053/j.gastro.2014.11.039
8. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995; 22(6):696-699. pmid:7560864
9. Bedossa P, Poinard T. An algorithm for the grading of activity in

- chronic hepatitis C. *Hepatology* 1996; 24(2):289–293. doi:10.1002/hep.510240201
10. **Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network.** Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; 41(6):1313–1321. doi:10.1002/hep.20701
 11. **Everhart JE, Wright EC, Goodman ZD, et al; HALT-C Trial Group.** Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. *Hepatology* 2010; 51(2):585–594. doi:10.1002/hep.23315
 12. **Angulo P, Kleiner DE, Dam-Larsen S, et al.** Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015; 149(2):389–397.e10. doi:10.1053/j.gastro.2015.04.043
 13. **Lindor KD, Bru C, Jorgensen RA, et al.** The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. *Hepatology* 1996; 23(5):1079–1083. doi:10.1002/hep.510230522
 14. **Pasha T, Gabriel S, Therneau T, Dickson ER, Lindor KD.** Cost-effectiveness of ultrasound-guided liver biopsy. *Hepatology* 1998; 27(5):1220–1226. doi:10.1002/hep.510270506
 15. **Alessandria C, Debernardi-Venon W, Rizzetto M, Marzano A.** Transjugular liver biopsy: a relatively simple procedure with an indefinite past and an expected brilliant future. *J Hepatol* 2008; 48(1):171–173. doi:10.1016/j.jhep.2007.10.001
 16. **Kalambokis G, Manousou P, Vibhakorn S, et al.** Transjugular liver biopsy—indications, adequacy, quality of specimens, and complications—a systematic review. *J Hepatol* 2007; 47(2):284–294. doi:10.1016/j.jhep.2007.05.001
 17. **Ripoll C, Groszmann R, Garcia-Tsao G, et al; Portal Hypertension Collaborative Group.** Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 2007; 133(2):481–488. doi:10.1053/j.gastro.2007.05.024
 18. **Perrault J, McGill DB, Ott BJ, Taylor WF.** Liver biopsy: complications in 1000 inpatients and outpatients. *Gastroenterology* 1978; 74(1):103–106. pmid:618417
 19. **Janes CH, Lindor KD.** Outcome of patients hospitalized for complications after outpatient liver biopsy. *Ann Intern Med* 1993; 118(2):96–98. pmid:8416324
 20. **Bedossa P, Dargere D, Paradis V.** Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003; 38(6):1449–1457. doi:10.1016/j.jhep.2003.09.022
 21. **Regev A, Berho M, Jeffers LJ, et al.** Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; 97(10):2614–2618. doi:10.1111/j.1572-0241.2002.06038.x
 22. **Goldin RD, Goldin JG, Burt AD, et al.** Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. *J Hepatol* 1996; 25(5):649–654. pmid:8938541
 23. **Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.** *Hepatology* 1994; 20(1 Pt 1):15–20. pmid:8020885
 24. **Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators.** Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; 43(6):1317–1325. doi:10.1002/hep.21178
 25. **Vallet-Pichard A, Mallet V, Nalpas B, et al.** FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. *Hepatology* 2007; 46(1):32–36. doi:10.1002/hep.21669
 26. **Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network.** Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009; 7(10):1104–1112. doi:10.1016/j.cgh.2009.05.033
 27. **McPherson S, Stewart SF, Henderson E, Burt AD, Day CP.** Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010; 59(9):1265–1269. doi:10.1136/gut.2010.216077
 28. **Angulo P, Hui JM, Marchesini G, et al.** The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007; 45(4):846–854. doi:10.1002/hep.21496
 29. **Goh GB, Pagadala MR, Dasarathy J, et al.** Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. *BBA Clin* 2015; 3:141–145. doi:10.1016/j.bbacli.2014.09.001
 30. **Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N.** Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. *PLoS One* 2016; 11(2):e0147237. doi:10.1371/journal.pone.0147237
 31. **Wai CT, Greenson JK, Fontana RJ, et al.** A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38(2):518–526. doi:10.1053/jhep.2003.50346
 32. **Calès P, Lainé F, Boursier J, et al.** Comparison of blood tests for liver fibrosis specific or not to NAFLD. *J Hepatol* 2009; 50(1):165–173. doi:10.1016/j.jhep.2008.07.035
 33. **Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group.** Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; 357(9262):1069–1075. doi:10.1016/S0140-6736(00)04258-6
 34. **Shaheen AA, Wan AF, Myers RP.** FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. *Am J Gastroenterol* 2007; 102(11):2589–2600. doi:10.1111/j.1572-0241.2007.01466.x
 35. **Smith JO, Sterling RK.** Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. *Aliment Pharmacol Ther* 2009; 30(6):557–576. doi:10.1111/j.1365-2036.2009.04062.x
 36. **Sebastiani G, Vario A, Guido M, Alberti A.** Performance of non-invasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. *J Viral Hepat* 2007; 15(3):212–218. doi:10.1111/j.1365-2893.2007.00932.x
 37. **Poynard T, Morra R, Halfon P, et al.** Meta-analyses of FibroTest diagnostic value in chronic liver disease. *BMC Gastroenterol* 2007; 7:40. doi:10.1186/1471-230X-7-40
 38. **Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL.** An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. *J Gastroenterol Hepatol* 2009; 24(5):786–791. doi:10.1111/j.1440-1746.2009.05778.x
 39. **Aubé C, Oberti F, Korali N, et al.** Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. *J Hepatol* 1999; 30(3):472–478. pmid:10190731
 40. **Di Lelio A, Cestari C, Lomazzi A, Beretta L.** Cirrhosis: diagnosis with sonographic study of the liver surface. *Radiology* 1989; 172(2):389–392. doi:10.1148/radiology.172.2.2526349
 41. **Wong VW, Chan HL.** Transient elastography. *J Gastroenterol Hepatol* 2010; 25(11):1726–1731. doi:10.1111/j.1440-1746.2010.06437.x
 42. **Arena U, Vizzutti F, Abraldes JG, et al.** Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. *Gut* 2008; 57(9):1288–1293. doi:10.1136/gut.2008.149708
 43. **Ziol M, Handra-Luca A, Kettaneh A, et al.** Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005; 41(1):48–54. doi:10.1002/hep.20506
 44. **Wong VW, Vergniol J, Wong GL, et al.** Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 2010; 51(2):454–462. doi:10.1002/hep.23312
 45. **Sagir A, Erhardt A, Schmitt M, Häussinger D.** Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *Hepatology* 2007; 48(2):592–595. doi:10.1002/hep.22056
 46. **Mederacke I, Wursthorn K, Kirschner J, et al.** Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. *Liver Int* 2009; 29(10):1500–1506. doi:10.1111/j.1478-3231.2009.02100.x
 47. **Castéra L, Foucher J, Bernard PH, et al.** Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology* 2010; 51(3):828–835. doi:10.1002/hep.23425
 48. **Wong VW, Vergniol J, Wong GL, et al.** Liver stiffness measurement

ASSESSING LIVER FIBROSIS

- using XL probe in patients with nonalcoholic fatty liver disease. *Am J Gastroenterol* 2012; 107(12):1862–1871. doi:10.1038/ajg.2012.331
49. **Fraquelli M, Rigamonti C, Casazza G, et al.** Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut* 2007; 56(7):968–973. doi:10.1136/gut.2006.111302
50. **de Franchis R; Baveno VI Faculty.** Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; 63(3):743–752. doi:10.1016/j.jhep.2015.05.022
51. **Friedrich-Rust M, Wunder K, Kriener S, et al.** Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. *Radiology* 2009; 252(2):595–604. doi:10.1148/radiol.2523081928
52. **Yoneda M, Suzuki K, Kato S, et al.** Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. *Radiology* 2010; 256(2):640–647. doi:10.1148/radiol.10091662
53. **Bota S, Herkner H, Sporea I, et al.** Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int* 2013; 33(8):1138–1147. doi:10.1111/liv.12240
54. **Attia D, Bantel H, Lenzen H, Manns MP, Gebel MJ, Potthoff A.** Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. *Aliment Pharmacol Ther* 2016; 44(4):366–379. doi:10.1111/apt.13710
55. **Cui J, Heba E, Hernandez C, et al.** Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. *Hepatology* 2016; 63(2):453–461. doi:10.1002/hep.28337
56. **Huwart L, Sempoux C, Vicaud E, et al.** Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* 2008; 135(1):32–40. doi:10.1053/j.gastro.2008.03.076
57. **Jajamovich GH, Dyvorne H, Donnerhack C, Taouli B.** Quantitative liver MRI combining phase contrast imaging, elastography, and DWI: assessment of reproducibility and postprandial effect at 3.0 T. *PLoS One* 2014; 9(5):e97355. doi:10.1371/journal.pone.0097355
58. **Lim JK, Flamm SL, Singh S, Falck-Ytter YT; Clinical Guidelines Committee of the American Gastroenterological Association.** American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis. *Gastroenterology* 2017; 152(6):1536–1543. doi:10.1053/j.gastro.2017.03.017
59. **Alkhoury N, Feldstein AE.** Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet? *Metabolism* 2016; 65(8):1087–1095. doi:10.1016/j.metabol.2016.01.013

ADDRESS: Arthur J. McCullough, MD, Department of Gastroenterology and Hepatology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mcculla@ccf.org



R.J. Fasanmyer Center for Clinical Immunology

Biologic Therapies VIII Summit:

The Intersection of Rheumatology and Allied Specialties
and 28th Annual Cleveland Review of Rheumatic Diseases



Featuring *Vasculitis: Multidisciplinary Care for Multisystem Diseases Symposium*

May 15-17, 2019 | Global Center for Health Innovation | Cleveland, OH

Why Attend?

- Join experts in discussions of recent and future targets
- Learn from diverse perspectives of multiple disciplines including rheumatology, dermatology, infectious disease, neurology, pulmonology, oncology, ophthalmology and wellness
- Expand and enhance decision-making skills for appropriate use of biologic therapies in management of complex multisystem disorders
- Learn the scientific basis of wellness behavior and immune function



KEYNOTE ADDRESS – R.J. Fasanmyer Annual Lectureship

Wellness in Medicine 2019 – Why Is It Important and Whose Job Is It?

Michael Roizen, MD, Cleveland Clinic

These activities have been approved for AMA PRA Category 1 Credit™.

For more information, visit www.ccfme.org/BioVIII